Dibay

DiBay is a clinical-stage biotechnology company specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary platform to design bifunctional molecules, such as PROTACs and molecular glues, that harness the body's natural ubiquitin-proteasome system to eliminate disease-causing proteins. DiBay's primary therapeutic focus is on oncology and immunology, with a pipeline targeting well-validated but difficult-to-treat drivers of cancer, including the androgen and estrogen receptors. Based in Suzhou, China, the company aims to overcome drug resistance associated with traditional small molecule inhibitors. DiBay continues to advance multiple programs through the pre-clinical stage toward IND-enabling studies.